- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | AROA BIOSURGERY LIMITED: Notification of Investor Webinar | - | ASX | ||
| 22.01. | AROA BIOSURGERY LIMITED: Study Demonstrates Effectiveness & Economic Value of Myriad | 1 | ASX | ||
| 09.01. | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | 1 | ASX | ||
| 18.12.25 | AROA BIOSURGERY LIMITED: Symphony Outpatient Reimbursement Update | - | ASX | ||
| 17.12.25 | Multi-channel sales strategy drives growth for tissue repair biotech Aroa | 7 | Stockhead | ||
| 25.11.25 | Aroa Biosurgery Reports NZ$44.9m in Product Revenue for First Six Months of FY26 | 1 | smallcaps.com.au | ||
| 25.11.25 | Health Check: It's quarterly report 'Liberation Day' for Aroa after a bumper first half result | 1 | Stockhead | ||
| 24.11.25 | AROA BIOSURGERY LIMITED: Aroa Half Year Results Presentation | - | ASX | ||
| AROA BIOSURGERY Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | AROA BIOSURGERY LIMITED: Aroa Biosurgery H1 FY26 Results | - | ASX | ||
| 24.11.25 | AROA BIOSURGERY LIMITED: Appendix 4D and Half Year Report | - | ASX | ||
| 12.11.25 | AROA BIOSURGERY LIMITED: Notification regarding unquoted securities - ARX | 2 | ASX | ||
| 11.11.25 | AROA BIOSURGERY LIMITED: Aroa Biosurgery H1 Results Webinar & Investor Event | - | ASX | ||
| 03.11.25 | AROA BIOSURGERY LIMITED: Initial Director's Interest Notice - PS | - | ASX | ||
| 03.11.25 | AROA BIOSURGERY LIMITED: Final Director's Interest Notice - JP | - | ASX | ||
| 31.10.25 | AROA BIOSURGERY LIMITED: Paul Shearer to join Aroa Board and John Pinion to Retire | 1 | ASX | ||
| 15.10.25 | AROA BIOSURGERY LIMITED: Investor Presentation | - | ASX | ||
| 15.10.25 | AROA BIOSURGERY LIMITED: September 2025 Quarterly Report and Appendix 4C | - | ASX | ||
| 10.10.25 | AROA BIOSURGERY LIMITED: Change in substantial holding | 1 | ASX | ||
| 09.10.25 | AROA BIOSURGERY LIMITED: Notification of Quarterly Results Webinar | 1 | ASX | ||
| 08.10.25 | AROA BIOSURGERY LIMITED: Notification of cessation of securities - ARX | 1 | ASX |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | BASF unter DRUCK! KAUFEMPFEHLUNGEN für BioNTech und WashTec Aktie! | Marktführerschaft, Effizienzsteigerung, Dividende und Aktienrückkauf - alles gute Gründe, um die Aktie von WashTec zu kaufen. Diese Einschätzung teilen auch die Analysten von MM Warburg. Ihre Gewinnschätzungen... ► Artikel lesen | |
| EVOTEC | 6,218 | -0,80 % | Evotec Aktie: Comebacktitel für 2026? | Aktionäre von Evotec müssen viel Geduld aufbringen. Seit Monaten scheitern immer wieder die Versuche der Biotech-Aktie, stabil über die 200-Tage-Linie zu springen. An oder knapp oberhalb des viel beachteten... ► Artikel lesen | |
| MODERNA | 36,760 | -1,17 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| HEIDELBERG PHARMA | 2,870 | +3,99 % | Heidelberg Pharma erhält Meilensteinzahlung von Takeda | Die Heidelberg Pharma AG hat im Rahmen einer bestehenden Lizenzvereinbarung eine Meilensteinzahlung von Takeda erhalten. Die Zahlung wurde mit der Dosierung des ersten Patienten in einer klinischen... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,370 | 0,00 % | INOVIO PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| SCORPIUS | 0,070 | 0,00 % | Scorpius Holdings, Inc. - 8-K, Current Report | ||
| TREVENA | 4,000 | +1.983 % | Hollywood Changemaker Oliver Trevena Joins Little Kitchen Academy as Investor | LOS ANGELES, CA / ACCESS Newswire / August 21, 2025 / Little Kitchen Academy (LKA), the premier Montessori-inspired cooking academy for children and teens ages 3-18, is proud to announce that Oliver... ► Artikel lesen | |
| DYNAVAX | 13,075 | +0,08 % | Laufende Fusionskontrollverfahren: Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USA | Datum der Anmeldung:05.01.2026Aktenzeichen:B3-21/26Unternehmen:Sanofi S.A., Paris/FR; mittelbarer Erwerb eines Mehrheitsanteils und alleiniger Kontrolle über die Dynavax Technologies Corporation, Delaware/USAProduktmärkte:monovalenter... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,360 | -0,73 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility | SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced... ► Artikel lesen | |
| IBIO | 1,810 | +1,12 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen | |
| VAXART | 0,370 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,466 | 0,00 % | Arbutus Biopharma Corporation: Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March 2026;Favorable claim construction ruling in Pfizer-BioNTech... ► Artikel lesen | |
| GALAPAGOS NV | 28,540 | +0,28 % | Galapagos NV: Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities | Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 3,190 | -1,54 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
AROA BIOSURGERY LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AROA BIOSURGERY LIMITED finden Sie auf Wallstreet Online.